Agilent Technologies (NYSE:A – Get Free Report) issued an update on its FY 2024 earnings guidance on Monday morning. The company provided EPS guidance of $5.44-$5.55 for the period, compared to the consensus EPS estimate of $5.41. The company issued revenue guidance of $6.71 billion-$6.81 billion, compared to the consensus revenue estimate of $6.82 billion. Agilent Technologies also updated its FY24 guidance to $5.44-5.55 EPS.
Agilent Technologies Stock Up 0.7 %
A opened at $113.98 on Tuesday. The company has a fifty day moving average price of $109.98 and a 200-day moving average price of $117.66. The firm has a market capitalization of $33.35 billion, a P/E ratio of 29.84, a price-to-earnings-growth ratio of 2.01 and a beta of 1.04. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.29 and a quick ratio of 1.68. Agilent Technologies has a one year low of $96.80 and a one year high of $160.26.
Agilent Technologies (NYSE:A – Get Free Report) last released its quarterly earnings results on Monday, November 20th. The medical research company reported $1.38 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. Agilent Technologies had a net margin of 16.20% and a return on equity of 29.86%. The firm had revenue of $1.69 billion during the quarter, compared to analyst estimates of $1.67 billion. During the same period in the previous year, the business earned $1.53 EPS. The business’s revenue for the quarter was down 8.7% on a year-over-year basis. Equities research analysts expect that Agilent Technologies will post 5.41 earnings per share for the current fiscal year.
Agilent Technologies Increases Dividend
Analyst Ratings Changes
Several brokerages recently issued reports on A. Robert W. Baird cut their target price on shares of Agilent Technologies from $144.00 to $140.00 and set an outperform rating for the company in a research report on Wednesday, August 16th. StockNews.com assumed coverage on shares of Agilent Technologies in a research report on Thursday, October 5th. They issued a buy rating for the company. Barclays lowered their price target on shares of Agilent Technologies from $110.00 to $105.00 and set an underweight rating for the company in a research note on Friday, September 29th. JPMorgan Chase & Co. lowered their price target on shares of Agilent Technologies from $155.00 to $150.00 and set an overweight rating for the company in a research note on Wednesday, August 16th. Finally, Credit Suisse Group lowered their price target on shares of Agilent Technologies from $160.00 to $150.00 and set an outperform rating for the company in a research note on Wednesday, August 16th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, Agilent Technologies has an average rating of Moderate Buy and an average target price of $143.94.
Insiders Place Their Bets
In other news, VP Rodney Gonsalves sold 3,500 shares of the stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $118.78, for a total transaction of $415,730.00. Following the sale, the vice president now owns 24,219 shares in the company, valued at $2,876,732.82. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 0.31% of the company’s stock.
Institutional Investors Weigh In On Agilent Technologies
Institutional investors have recently made changes to their positions in the company. Money Concepts Capital Corp purchased a new stake in Agilent Technologies in the fourth quarter worth approximately $26,000. Ancora Advisors LLC purchased a new stake in Agilent Technologies in the fourth quarter worth approximately $34,000. Resurgent Financial Advisors LLC purchased a new stake in Agilent Technologies in the fourth quarter worth approximately $57,000. Altshuler Shaham Ltd boosted its holdings in Agilent Technologies by 94.6% in the fourth quarter. Altshuler Shaham Ltd now owns 395 shares of the medical research company’s stock worth $59,000 after purchasing an additional 192 shares during the last quarter. Finally, Penserra Capital Management LLC purchased a new stake in Agilent Technologies in the first quarter worth approximately $60,000. Hedge funds and other institutional investors own 85.42% of the company’s stock.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies.
- Five stocks we like better than Agilent Technologies
- What Are Meme Stocks and Are They Viable Investments?
- Safeguard your portfolio with these three bargain stocks
- What Does Downgrade Mean in Investing?
- Membership clubs gain leverage for the consumer rebound
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.